Symphony Financial Ltd. Co. raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,898 shares of the company’s stock after buying an additional 345 shares during the quarter. Symphony Financial Ltd. Co.’s holdings in Zoetis were worth $638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in ZTS. Jeppson Wealth Management LLC acquired a new position in Zoetis in the third quarter worth about $25,000. Demars Financial Group LLC acquired a new stake in Zoetis during the 2nd quarter valued at $30,000. Arlington Partners LLC acquired a new stake in shares of Zoetis in the fourth quarter worth $32,000. Newfound Research LLC purchased a new position in shares of Zoetis during the third quarter valued at $34,000. Finally, Crewe Advisors LLC increased its stake in Zoetis by 533.3% in the 3rd quarter. Crewe Advisors LLC now owns 209 shares of the company’s stock valued at $35,000 after buying an additional 176 shares during the period. Hedge funds and other institutional investors own 92.50% of the company’s stock.

Shares of NYSE ZTS traded down $1.86 during mid-day trading on Wednesday, reaching $164.26. 54,042 shares of the company were exchanged, compared to its average volume of 1,557,931. Zoetis Inc. has a twelve month low of $90.14 and a twelve month high of $176.64. The company’s 50-day simple moving average is $162.17 and its 200-day simple moving average is $158.00. The company has a quick ratio of 2.60, a current ratio of 3.47 and a debt-to-equity ratio of 2.41. The stock has a market capitalization of $78.07 billion, a P/E ratio of 48.65, a P/E/G ratio of 4.35 and a beta of 0.71.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 5th. The company reported $1.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.19. Zoetis had a net margin of 25.50% and a return on equity of 63.89%. The firm had revenue of $1.79 billion during the quarter, compared to the consensus estimate of $1.63 billion. During the same quarter in the previous year, the firm posted $0.94 EPS. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. As a group, equities research analysts expect that Zoetis Inc. will post 3.63 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, March 1st. Investors of record on Wednesday, January 20th will be given a dividend of $0.25 per share. The ex-dividend date is Tuesday, January 19th. This represents a $1.00 dividend on an annualized basis and a yield of 0.61%. This is an increase from Zoetis’s previous quarterly dividend of $0.20. Zoetis’s dividend payout ratio is currently 21.98%.

ZTS has been the subject of several recent research reports. Truist increased their price objective on Zoetis from $160.00 to $170.00 in a report on Thursday, November 12th. BidaskClub upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Thursday, December 31st. Atlantic Securities began coverage on shares of Zoetis in a research note on Monday, September 21st. They set an “overweight” rating and a $191.00 price target on the stock. Barclays lifted their price objective on shares of Zoetis from $175.00 to $189.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Finally, Morgan Stanley increased their target price on shares of Zoetis from $167.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, November 13th. Eight analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Zoetis currently has a consensus rating of “Buy” and an average price target of $161.14.

In other news, Director Juan Ramon Alaix sold 91,747 shares of the business’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $165.46, for a total transaction of $15,180,458.62. Following the completion of the transaction, the director now owns 26,694 shares of the company’s stock, valued at approximately $4,416,789.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Heidi C. Chen sold 1,179 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $161.43, for a total value of $190,325.97. Following the sale, the executive vice president now owns 17,514 shares of the company’s stock, valued at $2,827,285.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 110,606 shares of company stock worth $18,241,735. Corporate insiders own 0.17% of the company’s stock.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: What is meant by buying and selling pressure?

Want to see what other hedge funds are holding ZTS? Visit to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with's FREE daily email newsletter.